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Abstract
Background:  Osteosarcoma is a highly malignant bone tumor and is the most commonly
encountered malignant bone tumor in children and adolescents. Furthermore, significant numbers
of patients eventually develop pulmonary metastases and succumb to the disease even after
conventional multi-agent chemotherapy and surgical excision. Several solid tumors display
enhanced expression of matrix metalloproteinases (MMPs), and recently clinical trials have been
initiated on MMP-inhibitors. On the other hand, bisphosphonates (BPs), which have a profound
effect on bone resorption, are widely used to treat osteoclast-mediated bone diseases. BPs are also
known to inhibit tumor growths and metastases in some tumors such as breast cancer, renal cell
carcinoma, and prostate cancer.
Methods: Two osteosarcoma cell lines (SaOS-2 and U2OS) were treated with risedronate (0, 0.1,
1, 10 μM) for 48 hours. Cell viabilities were determined using MTT assay, the mRNA levels of MMP-
2 and MMP-9 were analyzed by reverse-transcription polymerase chain reaction, the amount of
MMP-2 and MMP-9 protein were analyzed by Westernblot, the activities of MMP-2 and MMP-9
were observed by Gelatin zymography, and Matrigel invasion assays were used to investigate the
invasive potential of osteosarcoma cell lines before and after risedronate treatment.
Results: The invasiveness of osteosarcoma cell lines (SaOS-2, U2OS) were reduced in a dose
dependent manner follow 48 hour treatment of up to 10 μM of the risedronate at which
concentration no cytotoxicity occurred. Furthermore, the gelatinolytic activities and protein and
mRNA levels of MMP-2 and MMP-9 were also suppressed by increasing risedronate
concentrations.
Conclusion: Given that MMP-2 and MMP-9 are instrumental in tumor cell invasion, our results
suggest the risedronate could reduce osteosarcoma cell invasion.
Background
Osteosarcoma is one of the most common primary malig-
nant tumors of bone and occurs mainly in adolescents
and young adults [1,2]. Recently, the prognosis of these
patients has improved substantially due to the develop-
ment of various adjuvant chemotherapies. However, these
chemotherapies are not fully effective, and as a result,
20% of all osteosarcoma patients still die owing to tumors
metastasis [3-5]. Despite the advances made at improving
survival over the last three decades, a limit appears to have
been reached [6]. As a consequence, many novel therapies
for osteosarcoma are being investigated.
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The matrix metalloproteinases (MMPs) are a family of
zinc-dependent endopeptidases that remodel and degrade
extracellular matrix (ECM). More than 25 MMPs have
been identified to date, and are classified based on their
substrate specificities and structural characteristics [7-9].
Furthermore, MMPs are considered to play important
roles in the matrix degradation for tumor growth, inva-
sion, and tumor-induced angiogenesis [10,11].
Tumor growth, invasion, and metastasis require tumor
cell proliferation, proteolytic digestion of the extracellular
matrix (ECM), cell migration through basement mem-
branes into the circulatory system, and extravasation and
growth at metastatic sites [12]. MMPs contribute to this
metastatic process by degrading basement membrane. In
addition, MMPs can, due to their proteolytic activities,
promote tumor growth by increasing the bioavailabilities
of growth factors in the ECM [11]. Furthermore, it is
becoming increasingly clear that MMPs play a central role
in ECM degradation [13]. Among MMPs, MMP-2 (gelati-
nase A) and MMP-9 (gelatinase B), are present in large
quantities in cancer tissues [14,15], and accumulating evi-
dence indicates that MMP-2 and MMP-9 play critical role
during tumor invasion and metastasis [14,16-20]. Fur-
thermore, Matrix metalloproteinases (MMPs) and their
endogenous inhibitors participate in the invasive process
of human osteosarcoma [21].
Bisphosphonates (BPs) are stable analogues of pyrophos-
phonate, and are potent inhibitors of osteoclast-mediated
bone resorption. They are widely used to treat metabolic
bone diseases, such as, Paget's disease [22] and hypercal-
cemia [23] and to treat postmenopausal osteoporosis
[24]. Recently, it was reported that BPs may significantly
help control the pain associated with bone tumors [25].
Preclinical evidence suggest that BPs have direct antitu-
mor effects on a variety of human cancer cells [26], and it
is known that they decrease cell proliferation in human
osteosarcoma cell line panels, disturb the cell cycle, and
induce the apoptosis of SaOS-2 cells [27,28]. These find-
ings suggest that BPs could play a beneficial adjuvant role
in the treatment of osteosarcoma. However, the inhibitory
effects of BPs on osteosarcoma cell have not been compre-
hensively studied, and therefore, in the present study, we
examined the effects of the third-generation BPs, risedro-
nate, on osteosarcoma cell invasion.
Methods
Reagents
Risedronate [1-hydroxy-2-(3-pyridinyl)ethylidene]bis
[phosphonic acid] was purchased from (Sanofi-Aventis,
Korea). A stock solution of risedronate was prepared in
phosphate-buffer saline (PBS). All other chemicals and
reagents used were of analytical grade.
Cell Culture
SaOS-2 and U2OS were purchased from the Korean Cell
Line Bank (KCLB). Cells were cultivated in Dulbecco's
Minimum Essential Medium (DMEM) supplemented
with 10% heat-inactivated fetal bovine serum (Gibco BRL,
Grand Island, NY). Cultures were maintained at 37°C in
a 5% CO2/95% air atmosphere. The medium was changed
every 2–3 days, and cells were passaged twice a week.
Risedronate treatment of SaOS-2 and U2OS cells
SaOS-2 and U2OS cells were seeded in 6-well plates at a
density of 2 × 105cells/well in DMEM/10% FBS overnight.
The cells were then washed and treated with different con-
centrations of risedronate (0, 0.1, 1, 10 μM) for 48-h at
37°C in 5% CO2. Conditioned media were then collected
and cells were harvested.
MTT cell viability assay
SaOS-2 and U2OS cells were seeded onto a 96-well cul-
ture plate at a density of 1 × 104 cells/well in 100 μl of
complete DMEM. On the second day of culture, media
were replaced with 100 μl of serum-free DMEM and rise-
dronate at concentrations of 0–10 μM. On the third day,
100  μl of 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphe-
nyltetrazolium bromide (MTT; Sigma, USA) was added to
each well and incubated for 4 h. Media were then dis-
carded and 100 μl of dimethyl sulfoxide (DMSO; Sigma)
was added. Absorbance was measured at 570 nm using an
ELISA reader.
In vitro invasion
SaOS-2 and U2OS cells (4 × 104) in 300 μl of serum free-
MEM were seeded into the upper chamber of a 10-well
chemotaxis chamber (Neuro Probe, USA) and complete
MEM was placed in the lower chamber, and a Matrigel-
coated membrane was inserted between the two cham-
bers. Following overnight incubation at 37°C, the
medium in the upper chamber was replaced with serum-
free MEM and cells were treated with risedronate at 0, 0.1,
1 and 10 μM for 48 hours incubation at 37°C in a 5% CO2
atmosphere. The synthetic MMPs inhibitor, Marimastat
(50  μg/mg) was also added to the upper chamber to
examine the effect of MMPs on in vitro invasion. The
applied concentration of Marimastat was not toxic to the
osteosarcoma cells (data not shown). Finally, membranes
were fixed and stained using a Hemacolor rapid staining
kit (Merck, Germany), and the cells from 5 random micro-
scopic fields (200 × magnification) were counted.
Gelatin zymography
Protein concentrations in conditioned media were deter-
mined using the bicinchonic acid method (BCA kit)
(Pierce, IL, USA). Conditioned media was mixed with a
equal volume of 4× sample buffer (200 mM Tris-HCl, 8%
SDS, 0.4% bromophenol blue, 40% glycerol), and elec-Journal of Experimental & Clinical Cancer Research 2009, 28:105 http://www.jeccr.com/content/28/1/105
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trophoresed on 8% SDS polyacrylamide gels containing 2
mg/ml of gelatin (type A, Sigma, St. Louis, MO, USA).
Gels were then washed twice for 30 min in 2.5% Triton X-
100 at room temperature, and incubated for 18 hours at
37°C in incubation buffer (50 mM Tris-HCl (pH 7.5), 5
mM CaCl2, and 200 mM NaCl). Gels were then stained
for 1 hour with 0.25% (w/v) Coomassie brilliant blue R-
250 (Bio-Rad) and then destained in destaining buffer
(10% acetic acid and 20% methanol).
Western blot analysis
Cells were treated with risedronate (0, 0.1, 1, 10 μM) for
48 h, scraped into 1× cell lysis buffer (Cell Signaling,
USA), and incubated for 10 min on ice. The resulting cell
lysates were cleared by centrifugation at 6,700 × g at 4°C
for 5 min. Supernatants, which contained cytosolic pro-
teins, were collected and protein concentrations were
measured using the bicinchonic acid method (BCA kit)
(Pierce, IL, USA). Cell lysates, containing same amounts
of protein, were mixed with equal volumes of 4× sample
loading buffer, boiled for 5 min, cooled on ice for 5 min,
and then analyzed by 10% SDS polyacrylamide gel elec-
trophoresis (SDS-PAGE). Separated proteins were trans-
ferred to a nitrocellulose membrane (Amersham Life
Science, UK), and then the membrane was blocked with
5% skimmed milk in 1× TBST [0.01 M Tris (pH 7.6), 0.1
M NaCl and 0.1% Tween-20] for 1 h at room temperature
with shaking and incubated with indicated primary anti-
bodies followed by HRP-conjugated secondary antibody.
The immunoreactive protein bands were developed using
the Enhanced Chemiluminescence (ECL Plus) system
(Amersham Bioscience, UK).
Reverse transcription-polymerase chain reaction
Cells treated with risedronate (0, 0.1, 1, 10 μM) for 48 h
and washed with ice-cold 1× phosphate buffered saline
(PBS) twice. Total RNA was extracted using TRIzol Rea-
gent (Invitrogen, USA), according to the manufacturer's
instructions. RNA (1 μg) was reverse-transcribed using the
Superscript™ First-Strand Synthesis System for RT-PCR
(Invitrogen, San Diego) at 37°C. The following primers
were used to determine target gene levels. β-actin (sense
5'-CTGGAGCATGCCCGTATTTA-3' and anti-sense 5'-TTT-
GGTCTTGCCACTTTTCC-3'), MMP-2 (sense 5'-CTCA-
GATCCGTGGTGAGATCT-3' and anti-sense 5'-
CTTTGGTTCTCCAGCTTCAGG-3') and MMP-9 (sense 5'-
AAGTGGCACCACCACAACAT-3' and anti-sense 5'-TTTC-
CCATCAGCATTGCCGT-3'). All primers were checked
against the GeneBank Database to ensure no cross-reactiv-
ity with other known human DNA sequences. PCR cycles
were performed using the following sequence: 94°C for 5
min, then 30 cycles of denaturation at 94°C for 1 minute,
annealing at 60°C (for MMP-2) or 58°C (for MMP-9) for
1 minute, and polymerization at 72°C for 1 minute), and
followed by 72°C for 7 minutes. RT-PCR products were
visualized on 1.2% agarose gels electrophoresed in 0.5
TAE buffer containing 0.5 μg/ml ethidium bromide.
Risedronate at concentrations up to 10 μM had no cytotoxic effect on either SaOS-2 or U2OS cells Figure 1
Risedronate at concentrations up to 10 μM had no cytotoxic effect on either SaOS-2 or U2OS cells. Both cell 
lines in serum-free MEM were treated or not with the indicated concentrations of risedronate and then incubated for 48 h 
before doing MTT assay for cell growth quantification. The bar graph shows the absorbance (expressed as percentages of con-
trols) measured at 570 nm on an ELISA reader (n = 3 independent experiments; mean ± standard deviation is shown).Journal of Experimental & Clinical Cancer Research 2009, 28:105 http://www.jeccr.com/content/28/1/105
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Statistical analysis
Band Intensities were quantified using Multi Gauge V3.0
and Scion Image software. Results are expressed as means
± standard deviations. Statistical significance was accepted
for p values of < 0.05 by the Kruskal-Wallis Test and
Mann-Whitney  U  test, and all statistical analyses were
reviewed independently by a statistician.
Results
The antiproliferative effects of risedronate on SaOS-2 and 
U2OS cells
MTT assays were used to determine the effects of risedro-
nate on osteosarcoma cell growth. Risedronate treatment
at 0 to 10 μM for 48-hours did not significantly inhibit the
growth of either cell-line (Fig. 1), demonstrating that it
has no significant effect on SaOS-2 or U2OS survival at a
concentration of 10 μM. Thus, we performed all subse-
quent experiments using risedronate concentrations
between 0 and 10 μM
Risedronate impedes the invasiveness of SaOS-2 and U2OS cells (A and B) Figure 2
Risedronate impedes the invasiveness of SaOS-2 and U2OS cells (A and B). A 10-well chemotaxis chamber was 
used to measure the effect of risedronate on invasiveness. A Matrigel-coated membrane was inserted between the upper and 
lower chambers, and stained using a Hemacolor rapid staining kit. Stained areas represented numbers of migrating cells. The 
numbers in the panels show the concentration of risedronate added. Images are representative of three independent experi-
ments. Bars (C) represent cells number (expressed as percentages of controls) of each image ± standard deviation.Journal of Experimental & Clinical Cancer Research 2009, 28:105 http://www.jeccr.com/content/28/1/105
Page 5 of 8
(page number not for citation purposes)
Risedronate suppressed the invasive capacities of SaOS-2 
and U2OS cells
We carried out Matrigel invasion assays after treating
SaOS-2 and U2OS cells with risedronate. Risedronate was
found to inhibit the invasive activities of both cell lines
dose-dependently (p < 0.05) (Fig. 2). We also examined
the MMP-inhibitor marimastat in the invasion assay to
investigate a possible relationship between invasion
capacity and MMP expression. Marimastat inhibit the
both cells invasion significantly (SaOS-2: 55 ± 6%, U2OS:
36 ± 4%, p < 0.05) (Fig. 3).
Risedronate reduced MMP-2 and MMP-9 activities in 
SaOS-2 and U2OS cells
Since MMP-2 and MMP-9 play a critical role in tumor cell
invasiveness, we examined the effect of risedronate on the
enzyme activities of MMP-2 and MMP-9. Accordingly, gel-
atin zymography was conducted using conditioned media
harvested from risedronate treated SaOS-2 and U2OS
cells. The gelatinolytic activities of both MMP-2 and
MMP-9 were found to be reduced in both cell lines after
treatment with increasing concentrations of risedronate,
which suggested that the reductions in cell invasion by
risedronate is a consequence of reductions in the activities
of MMP-2 and MMP-9 (p < 0.05) (Fig. 4).
MMP-inhibitor Marimastat (50 μg/mg) impedes the invasive- ness of SaOS-2 and U2OS cells Figure 3
MMP-inhibitor Marimastat (50 μg/mg) impedes the 
invasiveness of SaOS-2 and U2OS cells. Three different 
experiments with each cell line were performed. Bars repre-
sent the cell numbers (expressed as percentages of controls) 
of each image ± standard deviation. Abbreviations: C: con-
trol; M: Marimastat.
Risedronate inhibited the gelatinolytic activities of MMP-2 and MMP-9 Figure 4
Risedronate inhibited the gelatinolytic activities of MMP-2 and MMP-9. (A) Conditioned media harvested from 
SaOS-2 and U2OS cells treated for 48 h with the indicated concentrations of risedronate were analyzed by gelatin zymography. 
The white bands represent MMP-mediated gelatin digestion. The image is representative of three independent experiments. 
MMPs activities (expressed as percentages of controls) are shown in B (n = 3). Numbers in boxes represent the concentration 
of risedronate (in μM) added to cells. Bars represent the MMPs activities (expressed as percentages of controls) of each band 
± standard deviation.Journal of Experimental & Clinical Cancer Research 2009, 28:105 http://www.jeccr.com/content/28/1/105
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Risedronate reduced the expressions of MMP-2 and MMP-9 proteins in SaOS-2 and U2OS cells Figure 5
Risedronate reduced the expressions of MMP-2 and MMP-9 proteins in SaOS-2 and U2OS cells. (A) Cells were 
treated with the indicated concentrations of risedronate for 48 h, and then cell lysates were Western blotted. Beta-actin was 
used as a loading control. Images are representative of three independent experiments. B shows MMPs protein levels 
(expressed as percentages of controls) (n = 3). Numbers in the box represent the concentration of risedronate in μM added to 
the cells. Bars represent MMPs protein levels (expressed as percentages of controls) of each band ± standard deviation.
Risedronate suppressed the expressions of MMP-2 and MMP-9 mRNA in SaOS-2 and U2OS cells Figure 6
Risedronate suppressed the expressions of MMP-2 and MMP-9 mRNA in SaOS-2 and U2OS cells. (A) Cells were 
treated with the indicated concentrations of risedronate for 48 h and then processed for RT-PCR. Beta-actin was used as a 
loading control. Images are representative of three independent experiments. MMPs mRNA levers (expressed as percentages 
of controls) are shown in B (n = 3). Numbers in the box represent the concentration of risedronate in μM added to the cells. 
Bars represent MMPs mRNA levels (expressed as percentages of controls) of each band ± standard deviation.Journal of Experimental & Clinical Cancer Research 2009, 28:105 http://www.jeccr.com/content/28/1/105
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Risedronate reduced MMP-2 and MMP-9 protein levels in 
both cell lines
To investigate whether risedronate inhibits the expres-
sions of MMP-2 and MMP-9, SaOS-2 and U2OS cells were
treated with risedronate and MMP-2 and MMP-9 protein
levels were determined by Western blotting. As shown in
Fig. 5, Western blotting revealed that risedronate inhibit
MMP-2 and MMP-9 protein levels (p < 0.05).
Risedronate suppressed MMP-2 and MMP-9 mRNA levels 
in both cell lines
RT-PCR was used to determine whether risedronate sup-
presses MMP-2 and MMP-9 at the transcription levels.
Risedronate was found to attenuate MMP-2 and MMP-9
mRNA levels dose-dependent in both cell lines (p < 0.05)
(Fig. 6).
Discussion
Osteosarcoma is an aggressive malignant bone disorder
exerting a high potential to invade and metastasize. A
number of studies have demonstrated the beneficial
effects of bisphosphonates on bone metastases from dif-
ferent solid tumors, such as, those of the breast, prostate
and renal cell carcinoma [29,30]. In the majority of previ-
ous studies, first or second-generation bisphosphonates
have been examined at the relatively high concentrations
required to inhibit the cell proliferation of osteosarcoma
cells [31,32]. In addition, third-generation bisphospho-
nates have been reported to induce osteosarcoma cell
apoptosis. Evdokiou and colleagues studied the third-gen-
eration bisphosphonate, zoledronic acid (ZOL), and
found that it dose- and time-dependently decreased cell
proliferation in a panel of human osteosarcoma cell lines
[27], Tadahiko Kubo and Shoji Shimose reported that
minodronate and incadronate perturb the cell cycle and
induce the apoptosis of SaOS-2 cells [28]. However, the
molecular mechanism underlying inhibition by BPs has
not been determined. Cheng YY et al. reported that alen-
dronate reduces MMP-2 secretion and induces tumor cell
apoptosis in osteosarcoma [33], but the molecular targets
and modes of action of MMP-2 and MMP-9 inhibitors,
like risedronate, are substantially unknown. In the present
study, we found that risedronate suppresses cell invasion
and the gelatinolytic activities and protein and mRNA
expressions of MMP-2 and MMP-9 in the SaOS-2 and
U2OS osteosarcoma cell lines. Pia Heikkilä, in a study on
the inhibition and downregulation of MT1-MMP by
clodronate (a non-nitrogen-containing bisphosphonate)
suggested that these activities are related to reductions in
MG-63 osteosarcoma cell invasion and spread [34]. Pro-
MMP-2 can be activated by several mechanisms depend-
ing on stimulators and cell types. In particular, pro-MMP-
2 can be activated by highly expressed MT1-MMP and ade-
quately expressed TIMP-2 [35,36]. Accordingly, our
results indicate that further research is required on the
roles played by TIMP-2 and MT1-MMP.
MMP-9 is considered to be particularly good targets for
anticancer drugs because it degrades gelatins, which are
major components of the basement membrane. The
expression of MMP-9 correlated with an aggressive,
advanced invasive or metastatic tumor phenotype
[37,38]. In the present study, the MMP-inhibitor Marima-
stat significantly inhibited osteosarcoma cell invasion,
which suggest that MMPs are vital factor in osteosarcoma
invasion, and that risedronate suppressed the expressions
of MMP-2 and MMP-9. Accordingly, our findings demon-
strate that risedronate has anti-invasive and antimetastatic
activity via the inhibition of MMP-2 and MMP-9 activity
in human osteosarcoma cells. On the other hand, Ichi-
nose et al found that bisphosphonates alone do not influ-
ence the amount of MMP-2 produced by human
osteoblasts, which suggests that bisphosphonates sup-
press expression of MMPs in osteosarcoma cells but not in
normal human osteoblasts [39].
According our MTT assay results, risedronate at up to 10
μM had no significant cytotoxic effect on SaOS-2 or U2OS
cells. Therefore, given the known importance of MMP-2
and MMP-9 in tumor invasion, our findings suggest that
the inhibitory effect of risedronate on osteosarcoma cell
invasion is probably due to MMP inhibition rather than
tumor cell death.
Conclusion
This study suggests that risedronate downregulates the
expressions of MMP-2 and MMP-9 in osteosarcoma, and
that this is responsible for its effect on osteosarcoma cell
invasiveness. This report provides first evidence that rise-
dronate downregulates the expressions and activities of
MMP-2 and MMP-9 in osteosarcoma cells in vitro.
Abbreviations
BPs: bisphosphonates; MMPs: matrix metalloproteinases;
RT-PCR: Reverse transcription-polymerase chain reaction.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
In our study, all authors are in agreement with the content
of the manuscript. Each author's contribution to the
paper: XZF: First author, study design, data analysis,
experimental studies, manuscript editing. KYK: study
design, experimental studies, data analysis. JST: Corre-
sponding Author, study design, experimental studies, data
analysis, manuscript preparation.Journal of Experimental & Clinical Cancer Research 2009, 28:105 http://www.jeccr.com/content/28/1/105
Page 8 of 8
(page number not for citation purposes)
Acknowledgements
This study was supported by a grant (CRI08061-1) from Chonnam national 
university hospital research institute of clinical medicine.
References
1. Thompson RC Jr, Cheng EY, Clohisy DR, Perentesis J, Manivel C, Le
CT: Results of treatment for metastatic osteosarcoma with
neoadjuvant chemotherapy and surgery.  Clin Orthop 2002,
397:240-247.
2. Hauben EI, Arends J, Vandenbroucke JP, van Asperen CJ, Van Marck
E, Hogendoorn PC: Multiple primary malignancies in osteosar-
coma patients. Incidence and predictive value of osteosar-
coma subtype for cancer syndromes related with
osteosarcoma.  Eur J Human Genetics 2003, 11:611-618.
3. Link MP: Preoperative and adjuvant chemotherapy in oste-
osarcoma. In Frontiers of Osteosarcoma Research: Interdis-
ciplinary Survey of Clinical and Research Advances.  Edited by:
Novak JF, Mcmaster JH. Seattle: Hogrefe and Huber; 1993:41-49. 
4. Unni KK: Dahlin' BONE TUMORS General Aspects and Date
on 11, 0809 Cases.  5th edition. Philadelphia: Lippincott;
1996:143-183. 
5. Bacci G, Longhi A, Versari M, Mercuri M, Briccoli A, Picci P: Prog-
nostic factors for osteosarcoma of the extremity treated
with neoadjuvant chemotherapy: 15-year experience in 789
patients treated at a single institution.  Cancer 2006,
106:1154-1161.
6. Mankin HJ, Hornicek FJ, Rosenberg AE, Harmon DC, Gebhardt MC:
Survival data for 648 patients with osteosarcoma treated at
one institution.  Clin Orthop Relat Res 2004, 429:286-291.
7. Brinckerhoff CE, Matrisian LM: Matrix metalloproteinases: a tail
of a frog that became a prince.  Nat Rev Mol Cell Biol 2002,
3:207-214.
8. Egeblad M, Werb Z: New functions for the matrix metallopro-
teinases in cancer progression.  Nat Rev Cancer 2002, 2:161-174.
9. Visse R, Nagase H: Matrix metalloproteinases and tissue inhib-
itors of metalloproteinases: structure, function, and bio-
chemistry.  Circ Res 2003, 92:827-839.
10. Ortega N, Behonick D, Stickens D, Werb Z: How proteases regu-
late bone morphogenesis.  Ann NY Acad Sci 2003, 995:109-116.
11. Chambers AF, Matrisian LM: hanging views of the role of matrix
metalloproteinases in metastasis.  J Natl Cancer Inst 1997,
89:1260-1270.
12. Liotta LA, Kohn EC: The microenvironment of the tumour-
host interface.  Nature 2001, 411:375-379.
13. Libra M, Scalisi A, Vella N, Clementi S, Sorio R, Stivala F, Spandidos
DA, Mazzarino C: Uterine cervical carcinoma: role of matrix
metalloproteinases (review).  Int J Oncol 2009, 34:897-903.
14. Liotta LA, Tryggvason K, Garbisa S, Hart I, Foltz CM, Shafie S: Meta-
static potential correlates with enzymatic degradation of
basement membrane collagen.  Nature 1980, 284:67-68.
15. Giannelli G, Falk-Marzillier J, Schiraldi O, Stetler-Stevenson WG,
Quaranta V: Induction of cell migration by matrix metallopro-
teinase- 2 cleavage of laminin-5.  Science 1997, 277:225-228.
16. Turpeenniemi-Hujanen T, Thorgeirsson UP, Hart IR, Grant SS, Liotta
LA: Expression of collagenase IV (basement membrane col-
lagenase) activity in murine tumor cell hybrids that differ in
metastatic potential.  J Natl Cancer Inst 1985, 75:99-103.
17. Stetler-Stevenson WG, Hewitt R, Corcoran M: Matrix metallopro-
teinases and tumor invasion: from correlation and causality
to the clinic.  Semin Cancer Biol 1996, 7:147-154.
18. Arii S, Mise M, Harada T, Furutani M, Ishigami S, Niwano M, Mizumoto
M, Fukumoto M, Imamura M: Overexpression of matrix metallo-
proteinase 9 gene in hepatocellular carcinoma with invasive
potential.  Hepatology 1996, 24:316-322.
19. Giannelli G, Bergamini C, Marinosci F, Fransvea E, Quaranta M, Lupo
L, Schiraldi O, Antonaci S: Clinical role of MMP-2/TIMP-2 imbal-
ance in hepatocellular carcinoma.  Int J Cancer 2002, 97:425-431.
20. Klein G, Vellenga E, Fraaije MW, Kamps WA, de Bont ES: The pos-
sible role of matrix metalloproteinase (MMP)-2 and MMP-9
in cancer, e.g. acute leukemia.  Crit Rev Oncol Hematol 2004,
50:87-100.
21. Kähäri VM, Saarialho-Kere U: Matrix metalloproteinases and
their inhibitors in growth and invasion.  Ann Med 1999,
31:34-45.
22. Roux C, Dougados M: Treatment of patients with Paget's dis-
ease of Bone.  Drugs 1999, 58:823-830.
23. Fleisch H: Bisphosphonates. Pharmacology and use in the
treatment of tumour-induced hypercalcaemic and meta-
static bone disease.  Drugs 1991, 42:919-944.
24. Delmas PD: Treatment of postmenopausal osteoporosis.  Lan-
cet 2002, 359:2018-2026.
25. Montella L, Addeo R, Faiola V, Cennamo G, Guarrasi R, Capasso E,
Mamone R, Caraglia M, Del Prete S: Zoledronic acid in metastatic
chondrosarcoma and advanced sacrum chordoma: two case
reports.  J Exp Clin Cancer Res 2009, 28:7.
26. Russell RG, Rogers MJ: Bisphosphonates: from the laboratory
to the clinic and back again.  Bone 1990, 25:97-106.
27. Evdokiou A, Labrinidis A, Bouralexis S, Hay S, Findlay DM: Induction
of cell death of human osteogenic sarcoma cells by
zoledronic acid resembles anoikis.  Bone 2003, 33:216-228.
28. Kubo T, Shimose S, Matsuo T, Tanaka K, Yasunaga Y, Sakai A, Ochi
M: Inhibitory Effects of a New Bisphosphonate, Minodronate,
on Proliferation and Invasion of a Variety of Malignant Bone
Tumor Cells.  J Orthop Res 2006, 6:1138-1144.
29. Lipton A, Zheng M, Seaman J: Zoledronic acid delays the onset
of skeletal-related events and progression of skeletal disease
in patients with advanced renal cell carcinoma.  Cancer 2003,
98:962-969.
30. Lacerna L, Hohneker J: Zoledronic acid for the treatment of
bone metastases in patients with breast cancer and other
solid tumors.  Semin Oncol 2003, 30:150-160.
31. Mackie PS, Fisher JL, Zhou H, Choong PF: Bisphosphonates regu-
late cell growth and gene expression in the UMR 106-01
clonal rat osteosarcoma cell line.  Br J Cancer 2001, 84:951-958.
32. Sonnemann J, Eckervogt V, Truckenbrod B, Boos J, Winkelmann W,
van Valen F: The bisphosphonate pamidronate is a potent
inhibitor of human osteosarcoma cell growth in vitro.  Anti-
cancer Drugs 2001, 12:459-465.
33. Cheng YY, Huang L, Lee KM, Li K, Kumta SM: Alendronate regu-
lates cell invasion and MMP-2 secretion in human osteosar-
coma cell lines.  Pediatr Blood Cancer 2004, 42:410-415.
34. Heikkilä P, Teronen O, Hirn MY, Sorsa T, Tervahartiala T, Salo T,
Konttinen YT, Halttunen T, Moilanen M, Hanemaaijer R, Laitinen M:
Inhibition of matrix metalloproteinase-14 in osteosarcoma
cells by clodronate.  J Surg Res 2003, 111:45-52.
35. Sato H, Takino T, Okada Y, Cao J, Shinagawa A, Yamamoto E, Seiki
M: A matrix metalloproteinase expressed on the surface of
invasive tumour cells.  Nature 1994, 370:61-65.
36. Sternlicht MD, Werb Z: How matrix metalloproteinases regu-
late cell behavior.  Annu Rev Cell Dev Biol 2001, 17:463-516.
37. Hong S, Park KK, Magae J, Ando K, Lee TS, Kwon TK, Kwak JY, Kim
CH, Chang YC: Ascochlorin inhibits matrix metalloprotein-
ase-9 expression by suppressing activator protein-1-medi-
ated gene expression through the ERK1/2 signaling pathway:
inhibitory effects of ascochlorin on the invasion of renal car-
cinoma cells.  J Biol Chem 2005, 280:25202-25209.
38. Sato H, Seiki M: Regulatory mechanism of 92 kDa type IV col-
lagenase gene expression which is associated with invasive-
ness of tumor cells.  Oncogene 1993, 8:395-405.
39. Ichinose Y, Migita K, Nakashima T, Kawakami A, Aoyagi T, Eguchi K:
Effects of bisphosphonate on the release of MMP-2 from cul-
tured human osteoblasts.  Tohoku J Exp Med 2000,
192(2):111-118.